Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Interferon-alpha Medicine & Life Sciences
Philadelphia Chromosome Medicine & Life Sciences
Cytogenetics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Mesylates Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2006 2026

Research Output 1979 2017

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Talpaz, M. & 20 others Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Jones, M., Kornacki, D., Sun, K. & Kantarjian, H. Feb 22 2017 In : Journal of Hematology and Oncology. 10, 1, p. 1-14 14 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Placebos
Spleen
Safety
Splenomegaly

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Mascarenhas, J. O., Talpaz, M., Gupta, V., Foltz, L. M., Savona, M. R., Paquette, R., Turner, A. R., Coughlin, P., Winton, E., Burn, T. C., O'neill, P., Clark, J., Hunter, D., Assad, A., Hoffman, R. & Verstovsek, S. 2017 In : Haematologica. 102, 2, p. 327-335 9 p.

Research output: Contribution to journalArticle

Janus Kinase 1
Primary Myelofibrosis
Thrombocytopenia
Spleen
Erythrocyte Transfusion

Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma

Potu, H., Peterson, L. F., Kandarpa, M., Pal, A., Sun, H., Durham, A., Harms, P. W., Hollenhorst, P. C., Eskiocak, U., Talpaz, M. & Donato, N. J. Feb 15 2017 In : Nature Communications. 8, 14449

Research output: Contribution to journalArticle

Ubiquitination
Melanoma
Skin
Neoplasms
Transcription factors
1 Citations

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

Verstovsek, S., Talpaz, M., Ritchie, E., Wadleigh, M., Odenike, O., Jamieson, C., Stein, B., Uno, T. & Mesa, R. A. Sep 2 2016 In : Leukemia.

Research output: Contribution to journalArticle

Janus Kinase 2
Primary Myelofibrosis
Multicenter Studies
Dizziness
Drug-Related Side Effects and Adverse Reactions
11 Citations

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Talpaz, M. & 20 others Deininger, M. W., Hodgson, J. G., Shah, N. P., Cortes, J. E., Kim, D. W., Nicolini, F. E., Baccarani, M., Müller, M. C., Li, J., Parker, W. T., Lustgarten, S., Clackson, T., Haluska, F. G., Guilhot, F., Kantarjian, H. M., Soverini, S., Hochhaus, A., Hughes, T. P., Rivera, V. M. & Branford, S. Feb 11 2016 In : Blood. 127, 6, p. 703-712 10 p.

Research output: Contribution to journalArticle

Leukemia, Myeloid, Chronic Phase
Mutation
Protein-Tyrosine Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics